An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients With Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2018
At a glance
- Drugs TAK-164 (Primary)
- Indications Colorectal cancer; Gastrointestinal cancer
- Focus Adverse reactions; First in man
- Sponsors Takeda Oncology
- 07 Nov 2018 Planned End Date changed from 29 May 2022 to 29 Apr 2022.
- 07 Nov 2018 Planned primary completion date changed from 29 May 2022 to 29 Apr 2022.
- 31 Aug 2018 Biomarkers information updated